← brief for 2026-09-04 · Slowing decline

Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

Trial No results yet Not peer reviewed

Key takeaways

A new trial is starting for adults with type 2 diabetes and kidney damage from diabetes who also face higher heart risk. It tests treating heart, kidney and metabolic risks together, early and to set targets, against usual care. This is a small pilot that follows people for 12 months to see whether the approach is workable and safe. There are no results yet.

Who did this work

Run by Sunnybrook Health Sciences Centre.
Sites: Sunnybrook Health Sciences Centre

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-04
https://clinicaltrials.gov/study/NCT07434791